Jonathan G Amatruda1,2, Michelle M Estrella3,4,5, Amit X Garg6,7, Heather Thiessen-Philbrook8, Eric McArthur7, Steven G Coca9, Chirag R Parikh8, Michael G Shlipak4,10. 1. Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA, jonathan.amatruda@ucsf.edu. 2. Kidney Health Research Collaborative, San Francisco VA Health Care System & University of California, San Francisco, San Francisco, California, USA, jonathan.amatruda@ucsf.edu. 3. Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA. 4. Kidney Health Research Collaborative, San Francisco VA Health Care System & University of California, San Francisco, San Francisco, California, USA. 5. Division of Nephrology, Department of Medicine, San Francisco VA Health Care System, San Francisco, California, USA. 6. Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. 7. ICES, Toronto, Ontario, Canada. 8. Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 9. Icahn School of Medicine at Mount Sinai, New York, New York, USA. 10. Department of Medicine, San Francisco VA Health Care System, San Francisco, California, USA.
Abstract
INTRODUCTION: Urine alpha-1-microglobulin (Uα1m) elevations signal proximal tubule dysfunction. In ambulatory settings, higher Uα1m is associated with acute kidney injury (AKI), progressive chronic kidney disease (CKD), cardiovascular (CV) events, and mortality. We investigated the associations of pre- and postoperative Uα1m concentrations with adverse outcomes after cardiac surgery. METHODS: In 1,464 adults undergoing cardiac surgery in the prospective multicenter Translational Research Investigating Biomarker Endpoints for Acute Kidney Injury (TRIBE-AKI) cohort, we measured the pre-and postoperative Uα1m concentrations and calculated the changes from pre- to postoperative concentrations. Outcomes were postoperative AKI during index hospitalization and longitudinal risks for CKD incidence and progression, CV events, and all-cause mortality after discharge. We analyzed Uα1m continuously and categorically by tertiles using multivariable logistic regression and Cox proportional hazards regression adjusted for demographics, surgery characteristics, comorbidities, baseline estimated glomerular filtration rate, urine albumin, and urine creatinine. RESULTS: There were 230 AKI events during cardiac surgery hospitalization; during median 6.7 years of follow-up, there were 212 cases of incident CKD, 54 cases of CKD progression, 269 CV events, and 459 deaths. Each 2-fold higher concentration of preoperative Uα1m was independently associated with AKI (adjusted odds ratio [aOR] = 1.36, 95% confidence interval 1.14-1.62), CKD progression (adjusted hazard ratio [aHR] = 1.46, 1.04-2.05), and all-cause mortality (aHR = 1.19, 1.06-1.33) but not with incident CKD (aHR = 1.21, 0.96-1.51) or CV events (aHR = 1.01, 0.86-1.19). Postoperative Uα1m was not associated with AKI (aOR per 2-fold higher = 1.07, 0.93-1.22), CKD incidence (aHR = 0.90, 0.79-1.03) or progression (aHR = 0.79, 0.56-1.11), CV events (aHR = 1.06, 0.94-1.19), and mortality (aHR = 1.01, 0.92-1.11). CONCLUSION: Preoperative Uα1m concentrations may identify patients at high risk of AKI and other adverse events after cardiac surgery, but postoperative Uα1m concentrations do not appear to be informative.
INTRODUCTION: Urine alpha-1-microglobulin (Uα1m) elevations signal proximal tubule dysfunction. In ambulatory settings, higher Uα1m is associated with acute kidney injury (AKI), progressive chronic kidney disease (CKD), cardiovascular (CV) events, and mortality. We investigated the associations of pre- and postoperative Uα1m concentrations with adverse outcomes after cardiac surgery. METHODS: In 1,464 adults undergoing cardiac surgery in the prospective multicenter Translational Research Investigating Biomarker Endpoints for Acute Kidney Injury (TRIBE-AKI) cohort, we measured the pre-and postoperative Uα1m concentrations and calculated the changes from pre- to postoperative concentrations. Outcomes were postoperative AKI during index hospitalization and longitudinal risks for CKD incidence and progression, CV events, and all-cause mortality after discharge. We analyzed Uα1m continuously and categorically by tertiles using multivariable logistic regression and Cox proportional hazards regression adjusted for demographics, surgery characteristics, comorbidities, baseline estimated glomerular filtration rate, urine albumin, and urine creatinine. RESULTS: There were 230 AKI events during cardiac surgery hospitalization; during median 6.7 years of follow-up, there were 212 cases of incident CKD, 54 cases of CKD progression, 269 CV events, and 459 deaths. Each 2-fold higher concentration of preoperative Uα1m was independently associated with AKI (adjusted odds ratio [aOR] = 1.36, 95% confidence interval 1.14-1.62), CKD progression (adjusted hazard ratio [aHR] = 1.46, 1.04-2.05), and all-cause mortality (aHR = 1.19, 1.06-1.33) but not with incident CKD (aHR = 1.21, 0.96-1.51) or CV events (aHR = 1.01, 0.86-1.19). Postoperative Uα1m was not associated with AKI (aOR per 2-fold higher = 1.07, 0.93-1.22), CKD incidence (aHR = 0.90, 0.79-1.03) or progression (aHR = 0.79, 0.56-1.11), CV events (aHR = 1.06, 0.94-1.19), and mortality (aHR = 1.01, 0.92-1.11). CONCLUSION: Preoperative Uα1m concentrations may identify patients at high risk of AKI and other adverse events after cardiac surgery, but postoperative Uα1m concentrations do not appear to be informative.
Authors: Andrew D Rule; Hatem Amer; Lynn D Cornell; Sandra J Taler; Fernando G Cosio; Walter K Kremers; Stephen C Textor; Mark D Stegall Journal: Ann Intern Med Date: 2010-05-04 Impact factor: 25.391
Authors: Chirag R Parikh; Jeremy Puthumana; Michael G Shlipak; Jay L Koyner; Heather Thiessen-Philbrook; Eric McArthur; Kathleen Kerr; Peter Kavsak; Richard P Whitlock; Amit X Garg; Steven G Coca Journal: J Am Soc Nephrol Date: 2017-08-14 Impact factor: 10.121
Authors: Dipal M Patel; Heather Thiessen-Philbrook; Jeremiah R Brown; Eric McArthur; Dennis G Moledina; Sherry G Mansour; Michael G Shlipak; Jay L Koyner; Peter Kavsak; Richard P Whitlock; Allen D Everett; David J Malenka; Amit X Garg; Steven G Coca; Chirag R Parikh Journal: Am Heart J Date: 2019-12-03 Impact factor: 4.749
Authors: William R Zhang; Timothy E Craven; Rakesh Malhotra; Alfred K Cheung; Michel Chonchol; Paul Drawz; Mark J Sarnak; Chirag R Parikh; Michael G Shlipak; Joachim H Ix Journal: Ann Intern Med Date: 2018-10-23 Impact factor: 25.391
Authors: Rakesh Malhotra; Timothy Craven; Walter T Ambrosius; Anthony A Killeen; William E Haley; Alfred K Cheung; Michel Chonchol; Mark Sarnak; Chirag R Parikh; Michael G Shlipak; Joachim H Ix Journal: Am J Kidney Dis Date: 2018-10-02 Impact factor: 8.860
Authors: S B Ascher; R Scherzer; M M Estrella; A N Muiru; V K Jotwani; C Grunfeld; J Shigenaga; K A Spaulding; D K Ng; D Gustafson; A B Spence; A Sharma; M H Cohen; C R Parikh; J H Ix; M G Shlipak Journal: HIV Med Date: 2021-03-09 Impact factor: 3.094